675576-98-4
Chemical Structure
Nutlin-3a
Synonym(s): Rebemadlin
- CAS No.: 675576-98-4
- Formula:C30H30Cl2N4O4
- Molecular Weight:581.49
IUPAC Name: 4-((4S,5R)-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one
InChIKey: BDUHCSBCVGXTJM-WUFINQPMSA-N
SMILES: O=C(N1C(C2=C(C=C(C=C2)OC)OC(C)C)=N[C@H]([C@H]1C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl)N5CC(NCC5)=O
Biological Activity: Nutlin-3a (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC50=90 nM). Nutlin-3a inhibits MDM2-p53 interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. Nutlin-3a has the potential for the study of TP53 wild-type ovarian carcinomas[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nutlin-3a | 99.13% | Nutlin-3a (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC50=90 nM). Nutlin-3a inhibits MDM2-p53 interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. Nutlin-3a has the potential for the study of TP53 wild-type ovarian carcinomas. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nutlin-3a (Standard) | ≥98% | Nutlin-3a (Standard) is the analytical standard of Nutlin-3a (HY-10029). This product is intended for research and analytical applications. Nutlin-3a (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC50=90 nM). Nutlin-3a inhibits MDM2-p53 interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. Nutlin-3a has the potential for the study of TP53 wild-type ovarian carcinomas. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Crane EK, et al. Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas. PLoS One. 2015 Aug 6;10(8):e0135101. [Content Brief]
- [2]. Tovar C, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93. [Content Brief]
Keywords
